Sumitomo Pharma

Sumitomo Pharma Co., Ltd. (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.[5]

Sumitomo Pharma Co., Ltd.
TypePublic (K.K.)
TYO: 4506
IndustryBiotech & Pharmaceuticals
Predecessor
  • Dainippon Pharmaceutical
  • Sumitomo Pharmaceuticals
FoundedOctober 1, 2005 (merger of Dainippon Pharmaceutical & Sumitomo Pharmaceuticals)
Headquarters6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan
Key people
Masayo Tada, (President and CEO)
Products
RevenueIncrease US$3.76 billion (¥387.69 billion) (FY 2013)
Increase US$194.94 million (¥20.06 billion) (FY 2013)
Number of employees
7,009 (consolidated)
4,291 (non-consolidated) (as of June 30, 2014)
WebsiteOfficial website
Footnotes / references
[1][2][3][4]

The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly privately-owned company funded by individuals from Tokyo and Osaka, with the land and buildings lent by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi.

The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to post operating losses. In 1898 it was acquired by Osaka Seiyaku.

The company is most well known for producing Philopon during WWII for the Imperial Japanese military.

(Osaka Pharmaceutical).[6]

Another origin of the company began as Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical (holding 77.8% of the share as of 2006).[7] Dainippon and Sumitomo merged on October 1, 2005, to create Dainippon Sumitomo Pharma.[8] As a result, Sumitomo Chemical has 50.2% ownership in Dainippon Sumitomo Pharma as of March 31, 2014.[2]

On April 1, 2022, the company was renamed from Sumitomo Dainippon Pharma to Sumitomo Pharma.

Acquisitions and Consolidations

Sunovion (formerly Sepracor Inc.), was acquired by then-Sumitomo Dainippon Pharma in 2010 for $2.6B.[9]

In September 2016, the Sunovion subsidiary announced it would acquire Cynapsus Therapeutics for approximately $624 million, to expand Sunovion's central nervous system drug portfolio. With the deal, Sunovion would acquire Cynapsus’ then-Phase III Parkinson's disease candidate drug APL-130277,[10] a sublingual formulation of apomorphine.[11]

In September 2019, Sumitomo Dainippon Pharma announced a $3B upfront acquisition of five Roivant Sciences subsidiaries, including Urovant and Enzyvant[12]

In October 2022, Sumitomo Pharma announced the acquisition of all outstanding shares in Myovant, a former Roivant Sciences subsidiary it was previously a majority owner of, valuing the company at $2.9B.[13]

In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries to form Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies.[14]

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

  • Sumitomo Pharma (Previously-known as Dainippon Sumitomo Pharma)
    • Sumitomo Pharma America, Inc. (Reorganised 2023)[15]
      • Sunovion (Acq 2010)
      • IBF Biotechnics (Acq 1991)
      • New England Pharmaceuticals (Acq 1995)
      • Oryx Pharmaceuticals (Acq 2008)
      • Elevation Pharmaceuticals (Acq 2012)
      • Cynapsus Therapeutics (Acq 2016)
      • Sumitomo Pharma America Holdings, Inc.
      • Sumitomo Pharma Oncology, Inc.
      • Sumitovant Biopharma Ltd
        • Myovant Sciences, Inc. (Acq 2019)
        • Urovant Sciences, Inc. (Acq 2019)
        • Enzyvant Therapeutics, Inc. (Acq 2019)
        • Altavant Sciences, Inc. (Acq 2019)
      • Spirovant Sciences, Inc. (Acq 2019)
    • Boston Biomedical (Acq 2012)
    • Tolero Pharmaceuticals (Acq 2016)

References
  1. "Corporate Profile". Dainippon Sumitomo Pharma. Retrieved September 13, 2014.
  2. "Fact Book 2014" (PDF). Dainippon Sumitomo Pharma. Retrieved November 3, 2011.
  3. "Company Snapshot". Bloomberg Businessweek. Archived from the original on September 13, 2014. Retrieved September 13, 2014.
  4. "Company Profile". Bloomberg L.P. Retrieved September 13, 2014.
  5. "Company Summary". Google Finance. Retrieved September 13, 2014.
  6. Odagiri, Hiroyuki (1996). Technology and Industrial Development in Japan. Clarendon Press, Oxford. p. 239. ISBN 0-19-828802-6.
  7. 連結子会社の合併に関するお知らせ (PDF) (in Japanese). Sumitomo Chemical. November 25, 2004. Retrieved November 3, 2011.
  8. "Corporate History". Dainippon Sumitomo Pharma. Retrieved November 3, 2011.
  9. Company press release
  10. "Sunovion to Acquire Cynapsus for $624M - GEN News Highlights - GEN". September 2016.
  11. "Efficacy and Safety of APL-130277 in People with Parkinson's Disease who are Apomorphine Naïve | Parkinson's Disease".
  12. Roivant press release
  13. Myovant press release
  14. "Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America". Sumitovant. Retrieved 2023-07-10.
  15. "Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.